
Tomoyasu Fukui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6479684/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Dipeptidyl Peptidase-4 Inhibitor Inhibits Foam Cell Formation of Macrophages in Type 1 Diabetes via Suppression of CD36 and ACAT-1 Expression. International Journal of Molecular Sciences, 2020, 21, 4811.	1.8	20
2	TypeÂ1 diabetes patients have lower strength in femoral bone determined by quantitative computed tomography: A crossâ€sectional study. Journal of Diabetes Investigation, 2015, 6, 726-733.	1.1	19
3	Analysis of pancreatic volume in acuteâ€onset, slowlyâ€progressive and fulminant typeÂ1 diabetes in a Japanese population. Journal of Diabetes Investigation, 2018, 9, 1091-1099.	1.1	17
4	Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms. American Journal of Physiology - Endocrinology and Metabolism, 2019, 316, E895-E907.	1.8	17
5	Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study. Diabetes Therapy, 2019, 10, 215-228.	1.2	16
6	AGE-RAGE Axis Stimulates Oxidized LDL Uptake into Macrophages through Cyclin-Dependent Kinase 5-CD36 Pathway via Oxidative Stress Generation. International Journal of Molecular Sciences, 2020, 21, 9263.	1.8	11
7	Pancreatic ductal hyperplasia/dysplasia with obstructive chronic pancreatitis: an association with reduced pancreatic weight in type 1 diabetes. Diabetologia, 2016, 59, 865-867.	2.9	10
8	Comparison of liraglutide plus basal insulin and basal-bolus insulin therapy (BBIT) for glycemic control, body weight stability, and treatment satisfaction in patients treated using BBIT for type 2 diabetes without severe insulin deficiency: A randomized prospective pilot study. Diabetes Research and Clinical Practice, 2018, 140, 339-346.	1.1	10
9	Quadrant Analysis of Quantitative Computed Tomography Scans of the Femoral Neck Reveals Superior Region-Specific Weakness in Young and Middle-Aged Men With Type 1 Diabetes Mellitus. Journal of Clinical Densitometry, 2018, 21, 172-178.	0.5	10
10	Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-NaÃ⁻ve Patients with Type 2 Diabetes. Drugs in R and D, 2015, 15, 245-251.	1.1	9
11	Relationship between glucose variability evaluated by continuous glucose monitoring and clinical factors, including glucagon-stimulated insulin secretion in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 158, 107904.	1.1	9
12	Luseogliflozin inhibits high glucose-induced TGF- β 2 expression in mouse cardiomyocytes by suppressing NHE-1 activity. Journal of International Medical Research, 2022, 50, 030006052210974.	0.4	8
13	Increment of C-peptide after glucagon injection determines the progressive nature of Japanese type 2 diabetes: A long-term follow-up study. Endocrine Journal, 2013, 60, 715-724.	0.7	7
14	Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway. Biomedicines, 2021, 9, 832.	1.4	7
15	Circulating antiâ€glutamic acid decarboxylaseâ€65 antibody titers are positively associated with the capacity of insulin secretion in acuteâ€onset typeÂ1 diabetes with short duration in a Japanese population. Journal of Diabetes Investigation, 2019, 10, 1480-1489.	1.1	5
16	Anti-inflammatory and atheroprotective properties of glucagon. Diabetes and Vascular Disease Research, 2020, 17, 147916412096518.	0.9	5
17	Pancreatic fat accumulation evaluated by multidetector computed tomography in patients with typeÂ2 diabetes. Journal of Diabetes Investigation, 2020, 11, 1188-1196.	1.1	4
18	Glucose-dependent insulinotropic polypeptide inhibits cardiac hypertrophy and fibrosis in diabetic mice via suppression of TGF-β2. Diabetes and Vascular Disease Research, 2021, 18, 147916412199903.	0.9	4

#	Article	IF	CITATIONS
19	Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?. Diabetes/Metabolism Research and Reviews, 2021, 37, e3415.	1.7	3
20	Relationship Between Islet Autoantibodies and Pancreatic Volume in Type 1 Diabetes in Japanese Population. Diabetes and Endocrinology, 2019, 2, .	0.0	2
21	A higher body mass index attenuates the long-term HbA1c-lowering effects of liraglutide in type 2 diabetes patients treated using sulfonylurea-based therapy. Diabetology International, 2016, 7, 425-431.	0.7	1
22	Association between insulin-like growth factor 1 and pancreatic volume in type 1 and type 2 diabetes: cross-sectional study of a Japanese population. Growth Hormone and IGF Research, 2021, 59, 101396.	0.5	1